$GGAAF
NeuroMind AI Corp.

2024 Q1 Form 10-Q Financial Statement

#000121390024066269 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $30.00K $264.0K
YoY Change -88.64% 18.49%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $30.00K $30.00K
YoY Change 0.0% -86.54%
Operating Profit -$281.2K -$264.0K
YoY Change 6.49% 18.49%
Interest Expense $13.64K $1.617M
YoY Change -99.16% 9650.3%
% of Operating Profit
Other Income/Expense, Net $13.64K $1.617M
YoY Change -99.16% 9653.25%
Pretax Income -$267.5K $1.353M
YoY Change -119.78% -755.83%
Income Tax
% Of Pretax Income
Net Earnings -$267.5K $1.353M
YoY Change -119.78% -755.84%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.04 $0.06
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.057M
YoY Change -42.29%
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets $150.0K
YoY Change 89.05%
Inventory
Prepaid Expenses $150.0K
Receivables
Other Receivables
Total Short-Term Assets $1.207M
YoY Change -36.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.251M
YoY Change -99.51%
Other Assets
YoY Change
Total Long-Term Assets $1.251M
YoY Change -99.51%
TOTAL ASSETS
Total Short-Term Assets $1.207M
Total Long-Term Assets $1.251M
Total Assets $1.062M $2.459M
YoY Change -56.8% -99.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.041M
YoY Change 921.18%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $2.530M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.571M
YoY Change 1266.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.571M
Total Long-Term Liabilities $0.00
Total Liabilities $5.620M $5.571M
YoY Change 0.88% -61.1%
SHAREHOLDERS EQUITY
Retained Earnings -$5.521M -$4.265M
YoY Change 29.46%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.520M -$4.264M
YoY Change
Total Liabilities & Shareholders Equity $1.062M $2.459M
YoY Change -56.8% -99.05%

Cashflow Statement

Concept 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$267.5K $1.353M
YoY Change -119.78% -755.84%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$343.7K -$143.2K
YoY Change 140.01% -45.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $263.5M
YoY Change
Cash From Investing Activities $263.5M
YoY Change 53380.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $343.7K -$263.3M
YoY Change -100.13% 115353.09%
NET CHANGE
Cash From Operating Activities -$343.7K -$143.2K
Cash From Investing Activities $263.5M
Cash From Financing Activities $343.7K -$263.3M
Net Change In Cash $0.00 $0.00
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities -$343.7K -$143.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41138
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROMIND AI CORP.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1601264
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Bahnhofstrasse 3
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hergiswil Nidwalden
CY2024Q1 dei Entity Address Country
EntityAddressCountry
CH
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6052
CY2024Q1 dei City Area Code
CityAreaCode
+41
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
78 607 99 01
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
true
CY2024Q1 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
1062222 usd
CY2023Q4 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
1048582 usd
CY2024Q1 us-gaap Assets
Assets
1062222 usd
CY2023Q4 us-gaap Assets
Assets
1048582 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2875985 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2938522 usd
CY2024Q1 us-gaap Liabilities
Liabilities
5620162 usd
CY2023Q4 us-gaap Liabilities
Liabilities
5339011 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
962222 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
948582 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5520795 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5239644 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5520162 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5239011 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1062222 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1048582 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
251151 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
234009 usd
CY2024Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
30000 usd
CY2023Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
30000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-281151 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-264009 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13640 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1616602 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13640 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1616602 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-267511 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1352593 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5239011 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
13640 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-267511 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5520162 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-17914914 usd
CY2023Q1 ggaa Waiver Of Deferred Underwriting Fee
WaiverOfDeferredUnderwritingFee
13915000 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1616602 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1352593 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4263923 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-267511 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1352593 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13640 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1616602 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-58750 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-62537 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
62061 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-343688 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-143198 usd
CY2023Q1 us-gaap Proceeds From Collection Of Advance To Affiliate
ProceedsFromCollectionOfAdvanceToAffiliate
143198 usd
CY2023Q1 ggaa Proceeds Cash Withdrawn From Trust Account In Connection With Redemption
ProceedsCashWithdrawnFromTrustAccountInConnectionWithRedemption
263325414 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
263468612 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
129511 usd
CY2024Q1 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
214177 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
263325414 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
343688 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-263325414 usd
CY2023Q1 ggaa Waiver Of Deferred Underwriting Fee
WaiverOfDeferredUnderwritingFee
13915000 usd
CY2024Q1 ggaa Accretion Of Common Stock Subject To Redemption
AccretionOfCommonStockSubjectToRedemption
13640 usd
CY2023Q1 ggaa Accretion Of Common Stock Subject To Redemption
AccretionOfCommonStockSubjectToRedemption
1616602 usd
CY2024Q1 ggaa Fair Value Percentage
FairValuePercentage
0.80 pure
CY2024Q1 ggaa Public Share Price
PublicSharePrice
11.8
CY2023 ggaa Public Share Price
PublicSharePrice
11.64
CY2024Q1 ggaa Dissolution Expenses
DissolutionExpenses
100000 usd
CY2024Q1 us-gaap Common Stock Held In Trust
CommonStockHeldInTrust
263325414 usd
CY2024Q1 ggaa Trust Account Per Share
TrustAccountPerShare
10.45
CY2024Q1 us-gaap Deposits Assets
DepositsAssets
246605 usd
CY2024Q1 us-gaap Limited Liability Company Llc Or Limited Partnership Lp Predecessor Entity Ies To Business Combination
LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination
(i) the Assigned Patent Rights, including the Additional Rights, as such terms are defined in the Patent Purchase Agreement, and (ii) all other intellectual property rights acquired by the Sponsor under the Patent Purchase Agreement, and (b) the Company will pay to the Sponsor one thousand dollars ($1,000) and will assume and agree to perform and discharge all of the Sponsor’s obligations under the Patent Purchase Agreement, including the obligation to pay to MindMaze a purchase price of $21 Million (the “MindMaze IP Purchase Price”) on or prior to May 31, 2024 (the “Outside Date”) and the obligation to share certain revenues with MindMaze, on the terms and subject to the conditions set forth in the Patent Purchase Agreement (collectively, the “Transaction”).
CY2024Q1 ggaa Working Capital Deficit
WorkingCapitalDeficit
5600000 usd
CY2024Q1 us-gaap Payments For Loans
PaymentsForLoans
453000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
1062222 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
1048582 usd
CY2024Q1 us-gaap Common Stock Held In Trust
CommonStockHeldInTrust
263325414 usd
CY2024Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
10.45
CY2023Q3 us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.92 pure
CY2023Q3 ggaa Voting Power Of Ordinary Shares Issued
VotingPowerOfOrdinarySharesIssued
6426039 shares
CY2023Q3 ggaa Voting Power Of Ordinary Shares Outstanding
VotingPowerOfOrdinarySharesOutstanding
6426039 shares
CY2023Q3 us-gaap Deposits Assets
DepositsAssets
246605 usd
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.63
CY2021Q4 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
825000 shares
CY2021Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
25000 usd
CY2024Q1 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
453000 usd
CY2021Q4 ggaa Notes Payable Related Party Current And Noncurrent
NotesPayableRelatedPartyCurrentAndNoncurrent
200000 usd
CY2021Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
25000 usd
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
228000 usd
CY2022Q4 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
2530000 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
2530000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2400489 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30000 usd
CY2024Q1 ggaa Related Party Transaction Agreement Outstanding
RelatedPartyTransactionAgreementOutstanding
150000 usd
CY2023 ggaa Related Party Transaction Agreement Outstanding
RelatedPartyTransactionAgreementOutstanding
120000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1057397 usd
CY2024Q1 ggaa Advance To Sponsor
AdvanceToSponsor
214177 usd
CY2024Q1 ggaa Underwriting Discount Per Unit
UnderwritingDiscountPerUnit
0.55
CY2024Q1 us-gaap Other Underwriting Expense
OtherUnderwritingExpense
13900000 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2024Q1 us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.20 pure
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2024Q1 us-gaap Credit Derivative Liquidation Proceeds Percentage
CreditDerivativeLiquidationProceedsPercentage
0.60 pure
CY2024Q1 us-gaap Investment Company Total Return Market Value
InvestmentCompanyTotalReturnMarketValue
1.15 pure
CY2024Q1 us-gaap Investment Company Redemption Fee Per Share
InvestmentCompanyRedemptionFeePerShare
18
CY2024Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.01
CY2024Q1 ggaa Class Of Warrant Or Right Exercisable Entity May Redeem Redemption Written Notice Period
ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionWrittenNoticePeriod
P30D
CY2024Q1 us-gaap Share Price
SharePrice
18
CY2024Q1 ggaa Number Of Trading Days
NumberOfTradingDays
P20D
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2024Q1 us-gaap Proceeds From Collection Of Advance To Affiliate
ProceedsFromCollectionOfAdvanceToAffiliate
usd
CY2024Q1 ggaa Proceeds Cash Withdrawn From Trust Account In Connection With Redemption
ProceedsCashWithdrawnFromTrustAccountInConnectionWithRedemption
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2023Q1 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
usd
CY2024Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2024Q1 ggaa Waiver Of Deferred Underwriting Fee
WaiverOfDeferredUnderwritingFee
usd
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001865697

Files In Submission

Name View Source Status
0001213900-24-066269-index-headers.html Edgar Link pending
0001213900-24-066269-index.html Edgar Link pending
0001213900-24-066269.txt Edgar Link pending
0001213900-24-066269-xbrl.zip Edgar Link pending
ea0210809-10q_neuro.htm Edgar Link pending
ea021080901ex31-1_neuro.htm Edgar Link pending
ea021080901ex32-1_neuro.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ggaa-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ggaa-20240331_cal.xml Edgar Link unprocessable
ggaa-20240331_lab.xml Edgar Link unprocessable
ggaa-20240331_def.xml Edgar Link unprocessable
ea0210809-10q_neuro_htm.xml Edgar Link completed
ggaa-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable